Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Other Non-Current Liabilities (2018 - 2025)

Sangamo Therapeutics has reported Other Non-Current Liabilities over the past 10 years, most recently at $580000.0 for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $580000.0 for Q4 2025, down 37.83% from a year ago — trailing twelve months through Dec 2025 was $580000.0 (down 37.83% YoY), and the annual figure for FY2025 was $580000.0, down 37.83%.
  • Other Non-Current Liabilities for Q4 2025 was $580000.0 at Sangamo Therapeutics, down from $977000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for SGMO hit a ceiling of $7.6 million in Q3 2021 and a floor of $580000.0 in Q4 2025.
  • Median Other Non-Current Liabilities over the past 5 years was $1.2 million (2023), compared with a mean of $2.1 million.
  • Biggest five-year swings in Other Non-Current Liabilities: rose 22.93% in 2021 and later tumbled 82.9% in 2022.
  • Sangamo Therapeutics' Other Non-Current Liabilities stood at $1.2 million in 2021, then dropped by 0.82% to $1.2 million in 2022, then dropped by 1.66% to $1.2 million in 2023, then decreased by 21.4% to $933000.0 in 2024, then tumbled by 37.83% to $580000.0 in 2025.
  • The last three reported values for Other Non-Current Liabilities were $580000.0 (Q4 2025), $977000.0 (Q3 2025), and $962000.0 (Q2 2025) per Business Quant data.